-
1 Comment
Titan Medical Inc is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
Titan Medical Inc's total revenue rose by inf% to $10M since the same quarter in the previous year.
Its net income has dropped by 955.1% to $-21M since the same quarter in the previous year.
Finally, its free cash flow grew by 75.9% to $-604K since the same quarter in the previous year.
Based on the above factors, Titan Medical Inc gets an overall score of 4/5.
Industry | Medical Devices |
---|---|
Sector | Healthcare |
ISIN | CA88830X8199 |
CurrencyCode | CAD |
Exchange | TO |
Market Cap | 19M |
---|---|
Beta | 3.52 |
PE Ratio | None |
Dividend Yield | 0.0% |
Target Price | 10.29 |
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TMD.TO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024